APA

Bohl S., von Harsdorf S., Mulaw M., Hofmann S., Babiak A., Maier C. P., Schnell J., Hütter-Krönke L., Scholl K., Wais V., Schlenk R. F., Bullinger L., Ringhoffer M., Döhner H., Bunjes D., Bommer M. & Kuchenbauer F. (20180213). Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. : Bone marrow transplantation.

Chicago

Bohl S, von Harsdorf S, Mulaw M, Hofmann S, Babiak A, Maier C P, Schnell J, Hütter-Krönke L-M, Scholl K, Wais V, Schlenk R F, Bullinger L, Ringhoffer M, Döhner H, Bunjes D, Bommer M and Kuchenbauer F. 20180213. Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. : Bone marrow transplantation.

Harvard

Bohl S., von Harsdorf S., Mulaw M., Hofmann S., Babiak A., Maier C. P., Schnell J., Hütter-Krönke L., Scholl K., Wais V., Schlenk R. F., Bullinger L., Ringhoffer M., Döhner H., Bunjes D., Bommer M. and Kuchenbauer F. (20180213). Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. : Bone marrow transplantation.

MLA

Bohl S, von Harsdorf S, Mulaw M, Hofmann S, Babiak A, Maier C P, Schnell J, Hütter-Krönke L-M, Scholl K, Wais V, Schlenk R F, Bullinger L, Ringhoffer M, Döhner H, Bunjes D, Bommer M and Kuchenbauer F. Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. : Bone marrow transplantation. 20180213.